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Steroids during late preterm 
labor: Better later than never 
Steroids—even when administered in the last leg 
of the late preterm period—still reduce the likelihood 
of respiratory complications in newborns. 
PRACTICE CHANGER
Use steroids in women at risk of preterm 
delivery, even if they are 36 weeks, 6 days’ 
pregnant, because steroids may reduce 
respiratory complications in the newborn 
with minimal risk for neonatal or maternal 
complications.
Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al; NICHD Mater-
nal–Fetal Medicine Units Network. Antenatal betamethasone for wom-
en at risk for late preterm delivery. N Engl J Med. 2016;374:1311-1320.1
STRENGTH OF RECOMMENDATION
A: Based on a good quality randomized con-
trolled trial and consistent with a meta-analysis.
ILLUSTRATIVE CASE
A 21-year-old G1P0 at 35 weeks, 2 days of ges-
tation presents to labor and delivery reporting 
a “gush of clear fluid.” On exam, you confirm 
she has preterm rupture of membranes. She is 
contracting every 3 minutes and has a cervix 
dilated to 3 cm. Is there any neonatal benefit 
to providing corticosteroids in this late pre-
term period?
Approximately 12% of all births in the United States are the result of preterm labor,2 and 8% are born in the late 
preterm period, defined as 34 to 36 weeks’ 
gestation.3 To reduce the risk of neonatal 
death and respiratory complications, both 
the American College of Obstetricians and 
Gynecologists and the National Institutes of 
Health recommend a course of corticoste-
roids between 24 and 34 weeks’ gestation for 
women at increased risk of preterm deliv-
ery.2,4 Due to a lack of evidence from random-
ized controlled trials (RCTs) on the benefit of 
corticosteroids in late preterm labor, there 
have not been recommendations to extend 
this period.5 However, multiple studies have 
shown that babies born during the late pre-
term period have more neonatal complica-
tions than term newborns.6-8
A retrospective chart review of more than 
130,000 live births found newborns delivered 
between 34 and 36 weeks had higher rates of 
respiratory distress than those delivered at 
39 weeks (ventilator use dropped from 3.3% 
at 34 weeks to 0.3% at 39 weeks and transient 
tachypnea decreased from 2.4% at 34 weeks 
to 0.4% at 39 weeks).6 Another retrospective 
review of more than 230,000 newborns, of 
which 19,000 were born in the late preterm 
period, revealed that more neonates born 
between 34 and 36 weeks’ gestation had 
respiratory distress syndrome than neonates 
delivered at 39 weeks (10.5% at 34 weeks, 
6% at 35 weeks, 2.8% at 36 weeks vs 0.3% at 
39 weeks; P<.001 for the trend).8 
STUDY SUMMARY
Late preterm newborns breathe better 
with antenatal betamethasone 
This randomized placebo-controlled trial 
examined the effectiveness of betametha-
sone in preventing neonatal respiratory 
complications for 2831 women at high probabil-
ity of preterm delivery between 34 weeks and 
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36 weeks, 6 days of gestation. “High probabili-
ty of preterm delivery” was defined as preterm 
labor with intact membranes and at least 3 cm 
dilation or 75% cervical effacement; sponta-
neous rupture of membranes; or anticipated 
preterm delivery for any other indication 
either through induction or cesarean section 
between 24 hours and 7 days after the planned 
randomization. 
Patients were randomly assigned to 
receive either 2 intramuscular injections 
(12 mg each) of betamethasone or placebo, 
24 hours apart. The 2 doses were successfully 
given in 60% of the betamethasone group and 
59% of the placebo group. In 95% of the cases 
where the second dose was not given, it was 
because delivery occurred within 24 hours of 
the first dose. 
The primary outcome was the need for 
respiratory support within 72 hours of birth, 
which was defined as one or more of the fol-
lowing: the use of continuous positive airway 
pressure (CPAP) or high-flow nasal cannula 
for at least 2 consecutive hours, supplemental 
oxygen for at least 4 continuous hours, extra-
corporeal membrane oxygenation (ECMO), 
or mechanical ventilation.
The median time to delivery from 
enrollment was 31 to 33 hours, and 31.4% 
underwent cesarean delivery. In the inten-
tion-to-treat analysis, the primary outcome 
was significantly lower in the betametha-
sone group than in the placebo group (11.6% 
vs 14.4%; relative risk [RR]=0.80; 95% CI, 
0.66-0.97; P=.02; number needed to treat 
[NNT]=35). Secondary outcomes (severe 
complications, representing a composite of 
the use of CPAP or high-flow nasal cannula 
for at least 12 continuous hours, supplemen-
tal oxygen for at least 24 continuous hours, 
ECMO, mechanical ventilation, stillbirth, or 
neonatal death within 72 hours after delivery) 
were also lower in the betamethasone group 
(8.1% vs 12.1%; RR=0.67; 95% CI, 0.53-0.84; 
P<.001; NNT=25). The betamethasone group 
also had a lower risk of transient tachypnea of 
the newborn (6.7% vs 9.9%; RR=0.68; 95% CI, 
0.53-0.87; P=.002). 
There were no significant differences in 
the occurrence of maternal chorioamnionitis 
(about 2%) or endometritis (about 1%) between 
the groups. Hypoglycemia in the newborn 
occurred more in the betamethasone group 
(24% vs 15%; RR=1.6; 95% CI, 1.37-1.87; P<.001; 
number needed to harm [NNH]=11). The beta-
methasone group had 2 neonatal deaths: one 
from septic shock and the other from a struc-
tural cardiac anomaly and arrhythmia. 
WHAT’S NEW 
Betamethasone makes a difference  
even in the late, late preterm period
This study demonstrated clear benefit in 
neonatal respiratory outcomes when beta-
methasone vs placebo was used in the late 
preterm period. The findings were similar to 
those from the Antenatal Steroids for Term 
Elective Caesarean Section Research Team.9 
Their trial showed a reduction in respiratory 
complications in term neonates delivered 
via elective cesarean section to mothers who 
received antenatal betamethasone (NNT=37 
to prevent admission to a special care nursery 
with respiratory distress). The findings were 
also consistent with those of a recent meta- 
analysis (including this trial) evaluating the 
occurrence of respiratory complications 
with the use of antenatal betamethasone in 
women expected to deliver in the late preterm 
period or with a planned cesarean delivery at 
≥37 weeks’ gestation.10
CAVEATS
Neonates may develop hypoglycemia
The authors of the study reported an 
increased risk of hypoglycemia in the neonates 
receiving antenatal betamethasone. The long-
term implications of this are unclear, however, 
given that there was a reduction in intermedi-
ate care nursery and neonatal intensive care 
unit stays that were 3 days or longer in the 
betamethasone group. Also, there was no dif-
ference in hospital length of stay between the 
2 groups. In addition, it’s not clear if there are 
any long-term neonatal complications of beta-
methasone use in the late preterm period.
CHALLENGES TO IMPLEMENTATION
Challenges are negligible since 
betamethasone is readily available
There are minimal challenges to implement-
This study  
demonstrated 
clear benefit  
in neonatal 
respiratory 
outcomes when 
betamethasone 
vs placebo was 
used in the late 
preterm period.
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ing this strategy, as betamethasone is rou-
tinely used for preterm labor and is readily 
available on labor and delivery units.           JFP
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